Residual urine volume (mL) | |||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
Visit | Observed value | Change from baseline | |||||||||
Intervention (VISPO) n = 33 |
Comparator (SPO) n = 33 |
Placebo n = 33 | p-value** |
Intervention (VISPO) n = 33 | p-value* |
Comparator (SPO) n = 33 | p-value* |
Placebo n = 33 | p-value* | p-value** | |
Visit 1 | 112.55 ± 36.19 | 110.12 ± 34.71 | 114.17 ± 30.67 | 0.888(1) | −12.76 ± 14.44a | < 0.001 | −1.88 ± 10.93b | 0.331 | 1.11 ± 13.89b | 0.649 | < 0.001(1) |
Visit 3 | 99.79 ± 29.27 | 108.24 ± 33.22 | 115.28 ± 33.25 | 0.149(1) | |||||||
Qmax (mL/s) | |||||||||||
Visit | Observed value | Change from baseline | |||||||||
Intervention (VISPO) n = 33 |
Comparator (SPO) n = 33 |
Placebo n = 33 | p-value** |
Intervention (VISPO) n = 33 | p-value* |
Comparator (SPO) n = 33 | p-value* |
Placebo n = 33 | p-value* | p-value** | |
Visit 1 | 11.85 ± 2.06 | 12.33 ± 1.61 | 12.27 ± 1.92 | 0.522(1) | 2.42 ± 2.61a | < 0.001 | 0.48 ± 1.56b | 0.084 | −0.64 ± 2.28b | 0.118 | < 0.001(1) |
Visit 3 | 14.27 ± 2.54a | 12.82 ± 1.72b | 11.64 ± 1.41c | < 0.001(2) |